-
Tytuł:
-
Anti-carbamylated protein antibodies and skin involvement in patients with systemic sclerosis: An intriguing association.
-
Autorzy:
-
Favoino E; Department of Biomedical Sciences and Human Oncology (DIMO), Rheumatologic and Systemic Autoimmune Diseases Unit, University of Bari Medical School, Bari, Italy.
Prete M; Department of Biomedical Sciences and Human Oncology (DIMO), Rheumatologic and Systemic Autoimmune Diseases Unit, University of Bari Medical School, Bari, Italy.
Vettori S; Department of Clinical and Experimental Internal Medicine 'F. Magrassi-A. Lanzara', Rheumatology Section, University of Campania, Naples, Italy.
Corrado A; Department of Medical and Surgery Sciences, Rheumatology Unit, University of Foggia, Foggia, Italy.
Cantatore FP; Department of Medical and Surgery Sciences, Rheumatology Unit, University of Foggia, Foggia, Italy.
Valentini G; Department of Clinical and Experimental Internal Medicine 'F. Magrassi-A. Lanzara', Rheumatology Section, University of Campania, Naples, Italy.
Perosa F; Department of Biomedical Sciences and Human Oncology (DIMO), Rheumatologic and Systemic Autoimmune Diseases Unit, University of Bari Medical School, Bari, Italy.
-
Źródło:
-
PloS one [PLoS One] 2018 Dec 31; Vol. 13 (12), pp. e0210023. Date of Electronic Publication: 2018 Dec 31 (Print Publication: 2018).
-
Typ publikacji:
-
Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: San Francisco, CA : Public Library of Science
-
MeSH Terms:
-
Protein Carbamylation*
Autoantibodies/*blood
Scleroderma, Systemic/*blood
Skin/*metabolism
Adult ; Animals ; Cattle ; Female ; Fibrinogen/metabolism ; Humans ; Male ; Middle Aged ; Scleroderma, Systemic/pathology ; Skin/pathology
-
References:
-
Chem Biol. 2006 Feb;13(2):149-59. (PMID: 16492563)
Ann Rheum Dis. 2016 Aug;75(8):1494-500. (PMID: 26350884)
Reumatologia. 2017;55(1):4-9. (PMID: 28386136)
J Rheumatol. 1988 Feb;15(2):202-5. (PMID: 3361530)
Ann Med Interne (Paris). 1999 Jan;150(1):47-52. (PMID: 10093661)
Arthritis Res Ther. 2017 May 31;19(1):115. (PMID: 28569212)
PLoS One. 2013 Apr 22;8(4):e61453. (PMID: 23613856)
Int Rev Exp Pathol. 1977;17:1-47. (PMID: 849882)
Arthritis Rheum. 2003 Jun 15;49(3):399-412. (PMID: 12794797)
J Clin Invest. 1996 Jan 1;97(1):111-9. (PMID: 8550821)
J Autoimmun. 2017 Jun;80:77-84. (PMID: 28291659)
Ann Rheum Dis. 2007 Jul;66(7):966-9. (PMID: 17234649)
Clin Exp Immunol. 1988 Jun;72(3):450-6. (PMID: 3168322)
Autoimmun Rev. 2014 Mar;13(3):225-30. (PMID: 24176675)
Arthritis Res Ther. 2016 May 04;18(1):96. (PMID: 27145822)
N Engl J Med. 1981 Apr 2;304(14):823-7. (PMID: 7207511)
Medicine (Baltimore). 2016 Jun;95(25):e3931. (PMID: 27336883)
Proc Natl Acad Sci U S A. 2011 Oct 18;108(42):17372-7. (PMID: 21987802)
Immunol Res. 2015 Feb;61(1-2):24-30. (PMID: 25391608)
J Clin Lab Immunol. 1982 May;8(1):9-12. (PMID: 7047748)
Arthritis Rheum. 2013 Apr;65(4):911-5. (PMID: 23279976)
Am J Med. 1997 Feb;102(2):178-85. (PMID: 9217568)
J Clin Invest. 2007 Mar;117(3):557-67. (PMID: 17332883)
Arthritis Res Ther. 2014 Jan 28;16(1):R29. (PMID: 24472528)
Clin Exp Immunol. 1996 Dec;106(3):491-7. (PMID: 8973617)
Rheumatol Int. 2016 Jun;36(6):781-91. (PMID: 27038800)
Rheumatology (Oxford). 2017 Jul 1;56(7):1217-1226. (PMID: 28398552)
Kidney Int. 1992 May;41(5):1175-81. (PMID: 1319520)
Int J Mol Sci. 2016 Sep 08;17(9):. (PMID: 27618024)
Arthritis Res Ther. 2016 Dec 3;18(1):289. (PMID: 27912793)
J Rheumatol. 2016 Feb;43(2):273-281. (PMID: 26669911)
Am J Kidney Dis. 2014 Nov;64(5):793-803. (PMID: 25037561)
Proc Natl Acad Sci U S A. 2016 Feb 2;113(5):1191-6. (PMID: 26712018)
Arthritis Rheum. 2013 Nov;65(11):2737-47. (PMID: 24122180)
Curr Opin Immunol. 2007 Dec;19(6):640-5. (PMID: 18083509)
Arthritis Res Ther. 2014 Jan 29;16(1):103. (PMID: 24472574)
Lupus. 2018 Jan;27(1):105-111. (PMID: 28592200)
Ann Rheum Dis. 2011 Mar;70(3):530-6. (PMID: 21081526)
Arthritis Rheum. 2002 Jun;46(6):1602-13. (PMID: 12115192)
Int J Immunopathol Pharmacol. 2015 Mar;28(1):93-103. (PMID: 25816411)
Front Immunol. 2015 Apr 15;6:167. (PMID: 25926833)
Semin Arthritis Rheum. 2008 Oct;38(2):132-60. (PMID: 18221988)
Ann Rheum Dis. 2013 Jan;72(1):148-50. (PMID: 22843489)
Clin Chem. 2011 Nov;57(11):1499-505. (PMID: 21768218)
PLoS One. 2016 Aug 18;11(8):e0161141. (PMID: 27537849)
Arthritis Res Ther. 2016 Nov 25;18(1):276. (PMID: 27887639)
Arthritis Rheumatol. 2017 Jul;69(7):1381-1386. (PMID: 28296337)
Arthritis Rheum. 2008 Dec;58(12):3913-23. (PMID: 19035500)
-
Substance Nomenclature:
-
0 (Autoantibodies)
9001-32-5 (Fibrinogen)
-
Entry Date(s):
-
Date Created: 20190101 Date Completed: 20190520 Latest Revision: 20200309
-
Update Code:
-
20240105
-
PubMed Central ID:
-
PMC6312283
-
DOI:
-
10.1371/journal.pone.0210023
-
PMID:
-
30596753
-
Carbamylation is a post-translational modification that mostly affects proteins with low turnover, such as dermal proteins. Carbamylated proteins accumulate in skin in an age-dependent manner, contributing to tissue alterations. As dermis is affected by systemic sclerosis (SSc) and anti-carbamylated protein antibodies (anti-CarP Ab) are found in SSc patients, we sought to evaluate the specificity of anti-CarP Ab and their relationship with clinical parameters reflecting skin involvement in SSc. This study investigated serum samples and clinical data from 124 patients with SSc. Anti-CarP Ab were affinity purified from pooled SSc sera, and their specificity was assessed by western blotting and ELISA with carbamylated proteins from two species (human and bovine albumin; human fibrinogen). Anti-CarP Ab were measured in SSc serum samples and in 41 healthy aged-matched individuals. Affinity-purified anti-CarP Ab recognized carbamylated epitopes irrespective of the protein type or species origin. Anti-CarP Ab levels inversely correlated with the modified Rodnan skin score (mRss) (Spearman's R = -0.32, p<0.001), independently of patients' age. Receiver operating characteristics (ROC) analysis identified anti-CarP Ab cut-offs that best discriminated dichotomized clinical variables related to skin involvement: the only clinical variables that were significantly different between groups were mRss (p = 0.001) and scleredema (p<0.001). Low anti-CarP Ab levels were associated with worse skin involvement. Future prospective studies are needed to assess their usefulness in the clinical setting.
Competing Interests: The authors have declared that no competing interests exist.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.